5324882025-04-012025-06-305324882025-04-012025-06-30in-capmkt:OtherExpenses1Member5324882025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedMain BoardEquity2025-04-012026-03-312025-08-062025-07-26INRCroresQuarterlyFirst quarterSingle segmentManufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients2025-08-0610:20:002025-08-0611:35:00Not applicable2025-04-012025-06-30UnauditedConsolidated24100000000119000000025290000000101000000000-54000000034000000003000000011200000003850000000179600000007330000000073300000001910000000-30000000188000000005450000000000054500000003000000054800000005450000000054800000000530000000220.4920.490020.4920.491.The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025 (“Consolidated statement”) is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Consolidated statement has been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 06, 2025. The statutory auditors have carried out a limited review of the Consolidated statement and issued an unmodified report thereon. <BR> <BR> 2.The consolidated financial results include the financial results of Divi’s Laboratories Limited and its wholly owned subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”). <BR> <BR> 3.The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reporting business segment as per Ind AS 108. <BR> <BR> 4.The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. <BR> <BR> 5.**Financial results for the quarter ended 31.03.2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review. <BR> <BR> 6.Details of Forex gain/(loss) are as given below: ( in Crores) <BR> Quarter Ended Year Ended <BR> 30.06.2025 31.03.2025 30.06.2024 31.03.2025 <BR> Forex gain/(loss) 39 10 (1) 48 <BR> <BR> Forex gain has been included in other income and loss has been included in other expenses. <BR> Other Expenses3850000000Gain on Remeasurement of post-employment benefit obligations-10000000-100000000Gain on exchange differences in translating the financial statements of foreign operations4000000040000000030000000